Author

David Tung

Observed names: D. Tung, David CY Tung

Observed institutions: Cleveland Clinic, Mayo Clinic, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Pfizer (United States)

OpenAlex ID: A5111797211

Specific down‐regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes

2007 · Mausumee Guha, Zhong‐Gao Xu, et al. · The FASEB Journal · 188

383 First-in-man clinical trial of intratumoral injection of clostridium Novyi-NT spores in combination with pembrolizumab in patients with treatment-refractory advanced solid tumors

2020 · Filip Janku, Siqing Fu, et al. · Regular and Young Investigator Award Abstracts · 15

Targeting Hedgehog In Cancer Stem Cells: How A Paradigm Shift Can Improve Treatment Response

2007 · David CY Tung, KS Clifford Chao · Future Oncology · 11

Phase I clinical study of intratumoral injection of oncolytic Clostridium novyi-NT spores in patients with advanced cancers

2016 · F. Janku, R. Murthy, et al. · European Journal of Cancer · 8

Abstract A011: First-in-man clinical trial of intratumoral injection of Clostridiumnovyi-NT spores in patients with treatment-refractory advanced solid tumors: Safety, activity, and immune responses

2019 · Filip Janku, Mrinal Gounder, et al. · Cancer Immunology Research · 1

Works count: 6

Citation count: 223

H-index: 4

I10-index: 3